<p><strong>Adjuvant Breast Cancer</strong>: Trastuzumab is indicated for adjuvant treatment of HER2 overexpressing node-positive or node-negative ER/PR negative or with one high-risk feature breast cancer</p>

<ul>
	<li>as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel</li>
	<li>as part of a treatment regimen with docetaxel and carboplatin</li>
	<li>as a single agent following multi-modality anthracycline-based therapy.</li>
</ul>

<p><strong>Metastatic Breast Cancer</strong>: Trastuzumab is indicated:</p>

<ul>
	<li>In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer</li>
	<li>As a single agent for treatment of HER2-overexpressing breast cancer in a patient who has received one or more chemotherapy regimens for metastatic disease. overexpressing breast cancer in patient.</li>
</ul>

<p><strong>Metastatic Gastric Cancer</strong>: Trastuzumab is indicated, in combination with cisplatin and<br />
capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing<br />
metastatic gastric or gastroesophageal junction adenocarcinoma who have not received<br />
prior treatment for metastatic disease.</p>